Legal & General Group Plc Has $101.25 Million Position in Insulet Corporation $PODD

Legal & General Group Plc lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 2.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 322,264 shares of the medical instruments supplier’s stock after selling 6,927 shares during the period. Legal & General Group Plc’s holdings in Insulet were worth $101,249,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. MAI Capital Management increased its stake in shares of Insulet by 2.9% during the 2nd quarter. MAI Capital Management now owns 2,127 shares of the medical instruments supplier’s stock worth $668,000 after purchasing an additional 59 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of Insulet in the 2nd quarter valued at $2,779,000. Magnetar Financial LLC bought a new stake in Insulet in the second quarter worth $9,439,000. Swiss National Bank increased its position in Insulet by 7.4% during the second quarter. Swiss National Bank now owns 212,600 shares of the medical instruments supplier’s stock worth $66,795,000 after buying an additional 14,700 shares during the last quarter. Finally, Prudential PLC raised its holdings in Insulet by 127.6% during the second quarter. Prudential PLC now owns 3,155 shares of the medical instruments supplier’s stock valued at $991,000 after buying an additional 1,769 shares in the last quarter.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of several recent analyst reports. Wells Fargo & Company upped their price target on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Truist Financial increased their price target on Insulet from $390.00 to $412.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Leerink Partners lifted their price objective on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $379.65.

Insulet Stock Up 1.9%

PODD opened at $337.53 on Tuesday. The company has a market capitalization of $23.74 billion, a P/E ratio of 102.59, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm’s fifty day moving average price is $322.16 and its two-hundred day moving average price is $316.00. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period last year, the firm earned $1.08 EPS. The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.